FDA Issues Guidance on Enforcement Priorities for Unauthorized ENDS and Nicotine Pouch Products

FDA Updates Enforcement Priorities for Unauthorized Tobacco Products

FDA’s Center for Tobacco Products (CTP) has issued guidance titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.”

The guidance outlines FDA’s current enforcement priorities for unauthorized electronic nicotine delivery systems (ENDS) and nicotine pouch products marketed without required premarket authorization.

Focus of the Guidance

According to FDA, the guidance is intended to support enforcement efforts involving products that may present increased concerns related to youth appeal, youth access, or unauthorized market entry.

The agency states that enforcement priorities include certain:

• Flavored ENDS products
• Disposable electronic nicotine delivery systems
• Nicotine pouch products marketed without authorization
• Products with characteristics that may increase youth appeal

Regulatory Background

Under the Federal Food, Drug, and Cosmetic Act, new tobacco products generally require FDA authorization prior to being legally marketed in the United States.

FDA evaluates whether products are appropriate for the protection of public health, taking into account both potential benefits for adult users and risks to youth populations.

What This Means for Industry

Manufacturers, importers, distributors, and retailers involved in ENDS and nicotine pouch products may wish to review the updated guidance and evaluate:

• Premarket authorization status of products
• Product portfolios involving flavored or disposable products
• Marketing practices and youth appeal considerations
• Compliance and enforcement risk exposure

The guidance reflects FDA’s continued focus on unauthorized products and youth-related enforcement priorities within the tobacco category.

EAS Perspective

FDA’s updated enforcement priorities reinforce the importance of maintaining clear regulatory strategies and understanding how product characteristics may influence enforcement risk.

Companies involved in tobacco and nicotine product development should continue monitoring FDA guidance and enforcement trends as the regulatory landscape evolves.